| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Scleroderma, Systemic | 27 | 2019 | 134 | 6.290 |
Why?
|
| Cadherins | 12 | 2022 | 660 | 4.200 |
Why?
|
| Arthritis, Rheumatoid | 10 | 2019 | 410 | 1.570 |
Why?
|
| Autoantibodies | 11 | 2019 | 576 | 1.460 |
Why?
|
| Skin | 6 | 2019 | 1259 | 1.270 |
Why?
|
| Pulmonary Fibrosis | 4 | 2022 | 170 | 1.260 |
Why?
|
| Antirheumatic Agents | 5 | 2017 | 167 | 1.210 |
Why?
|
| Skin Diseases | 3 | 2018 | 349 | 1.150 |
Why?
|
| Macrophages | 4 | 2022 | 1304 | 1.120 |
Why?
|
| Synovitis | 2 | 2020 | 23 | 1.050 |
Why?
|
| Transforming Growth Factor beta | 7 | 2019 | 1130 | 1.030 |
Why?
|
| Fibroblasts | 10 | 2019 | 1682 | 1.000 |
Why?
|
| Lupus Erythematosus, Systemic | 6 | 2023 | 223 | 0.930 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2022 | 49 | 0.830 |
Why?
|
| Fibrosis | 8 | 2022 | 793 | 0.830 |
Why?
|
| Kava | 1 | 2020 | 9 | 0.770 |
Why?
|
| Liver | 2 | 2022 | 2961 | 0.770 |
Why?
|
| Uveitis | 1 | 2020 | 33 | 0.760 |
Why?
|
| STAT3 Transcription Factor | 2 | 2018 | 1121 | 0.740 |
Why?
|
| Extracellular Matrix | 4 | 2019 | 554 | 0.730 |
Why?
|
| Arthritis | 1 | 2020 | 139 | 0.710 |
Why?
|
| Sarcoidosis | 1 | 2020 | 112 | 0.700 |
Why?
|
| Osteoarthropathy, Primary Hypertrophic | 1 | 2019 | 2 | 0.700 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2020 | 76 | 0.700 |
Why?
|
| Myofibroblasts | 3 | 2019 | 133 | 0.680 |
Why?
|
| Genetic Predisposition to Disease | 15 | 2019 | 5539 | 0.660 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 3 | 2015 | 168 | 0.660 |
Why?
|
| Naphthols | 1 | 2018 | 25 | 0.650 |
Why?
|
| Medical History Taking | 1 | 2019 | 173 | 0.650 |
Why?
|
| Monocytes | 1 | 2022 | 788 | 0.620 |
Why?
|
| Disease Models, Animal | 12 | 2022 | 7222 | 0.610 |
Why?
|
| Watchful Waiting | 1 | 2019 | 289 | 0.580 |
Why?
|
| Bleomycin | 6 | 2022 | 467 | 0.570 |
Why?
|
| Lung Diseases, Parasitic | 1 | 2016 | 14 | 0.560 |
Why?
|
| Strongyloides stercoralis | 1 | 2016 | 22 | 0.560 |
Why?
|
| Strongyloidiasis | 1 | 2016 | 24 | 0.560 |
Why?
|
| Polymorphism, Single Nucleotide | 12 | 2017 | 4549 | 0.540 |
Why?
|
| Pulmonary Alveoli | 1 | 2016 | 208 | 0.510 |
Why?
|
| Liver Cirrhosis | 1 | 2019 | 941 | 0.420 |
Why?
|
| Hypertension, Pulmonary | 3 | 2023 | 462 | 0.420 |
Why?
|
| Rheumatoid Factor | 1 | 2011 | 10 | 0.420 |
Why?
|
| Managed Care Programs | 1 | 2011 | 74 | 0.400 |
Why?
|
| Osteopontin | 1 | 2012 | 148 | 0.400 |
Why?
|
| CD58 Antigens | 1 | 2011 | 10 | 0.400 |
Why?
|
| Cell Differentiation | 3 | 2022 | 4078 | 0.400 |
Why?
|
| Hemorrhage | 1 | 2016 | 712 | 0.400 |
Why?
|
| Toll-Like Receptor 3 | 1 | 2011 | 23 | 0.390 |
Why?
|
| Animals | 23 | 2022 | 59536 | 0.390 |
Why?
|
| CD11c Antigen | 1 | 2011 | 55 | 0.390 |
Why?
|
| CD11b Antigen | 1 | 2011 | 66 | 0.390 |
Why?
|
| Cell Adhesion | 4 | 2022 | 1008 | 0.380 |
Why?
|
| Mice | 18 | 2022 | 34495 | 0.380 |
Why?
|
| Autoimmune Diseases | 2 | 2011 | 402 | 0.380 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2009 | 57 | 0.360 |
Why?
|
| OX40 Ligand | 1 | 2009 | 28 | 0.360 |
Why?
|
| Receptors, Interleukin | 1 | 2009 | 97 | 0.350 |
Why?
|
| Genetic Loci | 2 | 2011 | 481 | 0.350 |
Why?
|
| Sulfonamides | 1 | 2018 | 1823 | 0.350 |
Why?
|
| Autoimmunity | 1 | 2011 | 263 | 0.340 |
Why?
|
| Mice, Inbred C57BL | 9 | 2018 | 6942 | 0.330 |
Why?
|
| Cytokines | 6 | 2019 | 2809 | 0.330 |
Why?
|
| Mice, Knockout | 7 | 2019 | 5710 | 0.330 |
Why?
|
| Synovial Fluid | 1 | 2008 | 27 | 0.320 |
Why?
|
| Epithelial Cells | 1 | 2015 | 1818 | 0.320 |
Why?
|
| Humans | 55 | 2023 | 261506 | 0.320 |
Why?
|
| Severity of Illness Index | 5 | 2017 | 4320 | 0.310 |
Why?
|
| Immunologic Factors | 1 | 2011 | 649 | 0.310 |
Why?
|
| Withholding Treatment | 1 | 2008 | 161 | 0.300 |
Why?
|
| Inflammation | 2 | 2019 | 2522 | 0.290 |
Why?
|
| Interferon-alpha | 1 | 2011 | 889 | 0.280 |
Why?
|
| Interferon Regulatory Factor-7 | 2 | 2019 | 26 | 0.280 |
Why?
|
| Cell Communication | 2 | 2008 | 509 | 0.270 |
Why?
|
| Antibodies, Monoclonal | 5 | 2017 | 4367 | 0.270 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2011 | 973 | 0.270 |
Why?
|
| Stress, Psychological | 2 | 2011 | 1000 | 0.270 |
Why?
|
| Cells, Cultured | 5 | 2019 | 5637 | 0.260 |
Why?
|
| Lung | 2 | 2015 | 3151 | 0.260 |
Why?
|
| Myositis | 1 | 2005 | 79 | 0.250 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2010 | 1538 | 0.230 |
Why?
|
| Lipoblastoma | 1 | 2023 | 7 | 0.230 |
Why?
|
| Macrophages, Alveolar | 2 | 2014 | 67 | 0.230 |
Why?
|
| Cell Adhesion Molecules | 1 | 2006 | 577 | 0.220 |
Why?
|
| Antigens, CD | 1 | 2008 | 1385 | 0.220 |
Why?
|
| Male | 29 | 2022 | 123000 | 0.220 |
Why?
|
| Dermatologic Agents | 1 | 2023 | 53 | 0.220 |
Why?
|
| Psoriasis | 1 | 2023 | 126 | 0.210 |
Why?
|
| Antigens, Ly | 1 | 2022 | 49 | 0.210 |
Why?
|
| Antibodies, Antinuclear | 2 | 2011 | 46 | 0.200 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2019 | 709 | 0.200 |
Why?
|
| Myoclonus | 1 | 2021 | 34 | 0.200 |
Why?
|
| Sweet Syndrome | 1 | 2021 | 36 | 0.200 |
Why?
|
| Female | 27 | 2018 | 141928 | 0.190 |
Why?
|
| Genotype | 6 | 2011 | 4109 | 0.190 |
Why?
|
| Collagen | 3 | 2019 | 752 | 0.190 |
Why?
|
| B-Lymphocytes | 2 | 2019 | 1294 | 0.190 |
Why?
|
| Genome-Wide Association Study | 5 | 2012 | 2265 | 0.190 |
Why?
|
| Encephalitis | 1 | 2021 | 143 | 0.180 |
Why?
|
| Vitamin D | 2 | 2019 | 261 | 0.180 |
Why?
|
| Glomerulonephritis | 1 | 2020 | 109 | 0.180 |
Why?
|
| Carbon Tetrachloride | 1 | 2019 | 24 | 0.180 |
Why?
|
| Hepatic Stellate Cells | 1 | 2019 | 30 | 0.170 |
Why?
|
| Iron, Dietary | 1 | 2019 | 19 | 0.170 |
Why?
|
| HLA Antigens | 3 | 2011 | 546 | 0.170 |
Why?
|
| Purinergic P1 Receptor Antagonists | 1 | 2018 | 4 | 0.170 |
Why?
|
| Vitamins | 1 | 2019 | 157 | 0.160 |
Why?
|
| Lung Diseases, Interstitial | 2 | 2017 | 199 | 0.150 |
Why?
|
| Ustekinumab | 1 | 2017 | 1 | 0.150 |
Why?
|
| Hepatocytes | 1 | 2019 | 351 | 0.150 |
Why?
|
| Arthralgia | 1 | 2017 | 89 | 0.150 |
Why?
|
| Receptors, Calcitriol | 1 | 2017 | 134 | 0.150 |
Why?
|
| Synovial Membrane | 2 | 2007 | 41 | 0.150 |
Why?
|
| Chemokine CCL2 | 1 | 2017 | 203 | 0.140 |
Why?
|
| Dermis | 2 | 2016 | 65 | 0.140 |
Why?
|
| Interleukin-1beta | 1 | 2017 | 300 | 0.140 |
Why?
|
| Cohort Studies | 6 | 2017 | 9244 | 0.140 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2023 | 882 | 0.140 |
Why?
|
| Nanoparticles | 1 | 2020 | 554 | 0.130 |
Why?
|
| Aromatase Inhibitors | 1 | 2017 | 305 | 0.130 |
Why?
|
| Mice, 129 Strain | 2 | 2014 | 170 | 0.130 |
Why?
|
| Signal Transduction | 7 | 2019 | 11965 | 0.130 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2014 | 62 | 0.120 |
Why?
|
| Platelet Factor 4 | 1 | 2013 | 35 | 0.120 |
Why?
|
| Case-Control Studies | 6 | 2017 | 6100 | 0.110 |
Why?
|
| Biomarkers | 5 | 2022 | 5047 | 0.110 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2014 | 198 | 0.110 |
Why?
|
| Epistasis, Genetic | 2 | 2010 | 119 | 0.110 |
Why?
|
| Middle Aged | 13 | 2017 | 86204 | 0.110 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2011 | 182 | 0.110 |
Why?
|
| Receptors, Interleukin-12 | 1 | 2011 | 12 | 0.110 |
Why?
|
| Up-Regulation | 3 | 2019 | 2450 | 0.100 |
Why?
|
| Interferon Regulatory Factors | 1 | 2012 | 76 | 0.100 |
Why?
|
| Smad2 Protein | 1 | 2012 | 89 | 0.100 |
Why?
|
| Stress Disorders, Traumatic | 1 | 2011 | 8 | 0.100 |
Why?
|
| Gene Expression Profiling | 4 | 2010 | 5159 | 0.100 |
Why?
|
| France | 1 | 2011 | 108 | 0.100 |
Why?
|
| Toll-Like Receptor 5 | 1 | 2010 | 14 | 0.100 |
Why?
|
| Spondylitis, Ankylosing | 1 | 2010 | 29 | 0.100 |
Why?
|
| Neurosecretory Systems | 1 | 2011 | 66 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2010 | 2508 | 0.090 |
Why?
|
| Disease Progression | 3 | 2017 | 6682 | 0.090 |
Why?
|
| Treatment Failure | 2 | 2017 | 1391 | 0.090 |
Why?
|
| Transcriptome | 1 | 2019 | 1859 | 0.090 |
Why?
|
| STAT4 Transcription Factor | 1 | 2009 | 10 | 0.090 |
Why?
|
| Genetic Markers | 2 | 2011 | 974 | 0.090 |
Why?
|
| Interleukin-23 | 1 | 2009 | 29 | 0.090 |
Why?
|
| Interleukin-6 | 1 | 2014 | 1038 | 0.090 |
Why?
|
| Histocompatibility Testing | 2 | 2009 | 447 | 0.090 |
Why?
|
| Biopsy | 1 | 2017 | 3443 | 0.090 |
Why?
|
| Centromere | 1 | 2009 | 97 | 0.090 |
Why?
|
| CD3 Complex | 1 | 2010 | 314 | 0.090 |
Why?
|
| Epidemiologic Methods | 1 | 2009 | 254 | 0.090 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2010 | 203 | 0.090 |
Why?
|
| Adult | 12 | 2017 | 77950 | 0.080 |
Why?
|
| T-Box Domain Proteins | 1 | 2009 | 156 | 0.080 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2011 | 362 | 0.080 |
Why?
|
| Data Interpretation, Statistical | 1 | 2011 | 482 | 0.080 |
Why?
|
| Genetic Association Studies | 2 | 2010 | 1084 | 0.080 |
Why?
|
| Interferons | 1 | 2010 | 291 | 0.080 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2012 | 726 | 0.080 |
Why?
|
| Linkage Disequilibrium | 1 | 2009 | 460 | 0.080 |
Why?
|
| Leukocytes | 2 | 2010 | 422 | 0.080 |
Why?
|
| Interleukin-17 | 1 | 2009 | 250 | 0.080 |
Why?
|
| Social Support | 1 | 2011 | 560 | 0.080 |
Why?
|
| Dendritic Cells | 1 | 2013 | 1085 | 0.080 |
Why?
|
| Multiple Sclerosis | 1 | 2010 | 349 | 0.070 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 1217 | 0.070 |
Why?
|
| Alleles | 2 | 2011 | 2437 | 0.070 |
Why?
|
| Epitopes | 1 | 2009 | 685 | 0.070 |
Why?
|
| src-Family Kinases | 1 | 2009 | 478 | 0.070 |
Why?
|
| Adherens Junctions | 1 | 2006 | 20 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 4314 | 0.070 |
Why?
|
| Family | 1 | 2010 | 736 | 0.070 |
Why?
|
| Cell Movement | 1 | 2014 | 2466 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 1489 | 0.070 |
Why?
|
| Molecular Sequence Data | 2 | 2010 | 6089 | 0.070 |
Why?
|
| Prognosis | 3 | 2019 | 21713 | 0.070 |
Why?
|
| Lymphocyte Activation | 1 | 2010 | 1688 | 0.070 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 4892 | 0.060 |
Why?
|
| Risk Factors | 4 | 2011 | 17523 | 0.060 |
Why?
|
| Health Status | 1 | 2008 | 590 | 0.060 |
Why?
|
| rho-Associated Kinases | 2 | 2016 | 85 | 0.060 |
Why?
|
| Vital Capacity | 2 | 2017 | 131 | 0.060 |
Why?
|
| Double-Blind Method | 2 | 2023 | 2588 | 0.060 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2011 | 604 | 0.060 |
Why?
|
| Cell Line | 1 | 2011 | 5114 | 0.060 |
Why?
|
| Gene Frequency | 3 | 2011 | 1163 | 0.060 |
Why?
|
| Mesentery | 1 | 2023 | 72 | 0.060 |
Why?
|
| Child | 2 | 2023 | 29154 | 0.060 |
Why?
|
| Phenotype | 2 | 2011 | 6295 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2023 | 140 | 0.050 |
Why?
|
| Blood Sedimentation | 1 | 2022 | 35 | 0.050 |
Why?
|
| Truth Disclosure | 1 | 2003 | 180 | 0.050 |
Why?
|
| United States | 4 | 2012 | 15433 | 0.050 |
Why?
|
| Recurrence | 2 | 2010 | 4758 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 3719 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2011 | 2403 | 0.050 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 2020 | 23 | 0.050 |
Why?
|
| Mutation | 1 | 2020 | 15179 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2022 | 12873 | 0.050 |
Why?
|
| Lymphatic System | 1 | 2020 | 64 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 7548 | 0.040 |
Why?
|
| Receptors, Interleukin-15 | 1 | 2019 | 20 | 0.040 |
Why?
|
| Cyclosporine | 1 | 2020 | 278 | 0.040 |
Why?
|
| Europe | 2 | 2011 | 649 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2010 | 4053 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2023 | 3251 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2022 | 527 | 0.040 |
Why?
|
| Smad3 Protein | 1 | 2019 | 129 | 0.040 |
Why?
|
| Adolescent | 1 | 2019 | 31252 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2010 | 3869 | 0.040 |
Why?
|
| Physician-Patient Relations | 1 | 2003 | 792 | 0.040 |
Why?
|
| Androstadienes | 1 | 2017 | 165 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2023 | 1375 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2023 | 32848 | 0.040 |
Why?
|
| Tensile Strength | 1 | 2016 | 73 | 0.040 |
Why?
|
| Elastin | 1 | 2016 | 49 | 0.040 |
Why?
|
| Elastic Modulus | 1 | 2016 | 37 | 0.040 |
Why?
|
| Canada | 1 | 2017 | 429 | 0.030 |
Why?
|
| Retreatment | 1 | 2017 | 452 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 651 | 0.030 |
Why?
|
| Biomechanical Phenomena | 1 | 2016 | 338 | 0.030 |
Why?
|
| Physicians | 1 | 2003 | 882 | 0.030 |
Why?
|
| Aged | 5 | 2017 | 70117 | 0.030 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2013 | 21 | 0.030 |
Why?
|
| Fibronectins | 1 | 2014 | 197 | 0.030 |
Why?
|
| Muscle Development | 1 | 2014 | 88 | 0.030 |
Why?
|
| Feedback, Physiological | 1 | 2014 | 193 | 0.030 |
Why?
|
| Methotrexate | 1 | 2017 | 999 | 0.030 |
Why?
|
| Muscle Contraction | 1 | 2014 | 218 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 1077 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 15694 | 0.030 |
Why?
|
| Nanotechnology | 1 | 2013 | 137 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2014 | 292 | 0.030 |
Why?
|
| Peptides, Cyclic | 1 | 2013 | 139 | 0.030 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2014 | 330 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1945 | 0.030 |
Why?
|
| Immunogenetics | 1 | 2011 | 16 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2022 | 37905 | 0.020 |
Why?
|
| HLA-DRB1 Chains | 1 | 2011 | 82 | 0.020 |
Why?
|
| Urinary Bladder | 1 | 2014 | 575 | 0.020 |
Why?
|
| Mastectomy | 1 | 2017 | 1534 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2014 | 1764 | 0.020 |
Why?
|
| Ribonucleoprotein, U1 Small Nuclear | 1 | 2010 | 9 | 0.020 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2010 | 23 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2019 | 2295 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 2216 | 0.020 |
Why?
|
| Proteome | 1 | 2013 | 561 | 0.020 |
Why?
|
| Age of Onset | 1 | 2012 | 827 | 0.020 |
Why?
|
| Trans-Activators | 1 | 2016 | 1555 | 0.020 |
Why?
|
| Single-Cell Analysis | 1 | 2013 | 470 | 0.020 |
Why?
|
| Spain | 1 | 2009 | 113 | 0.020 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2010 | 110 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2017 | 3890 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 4988 | 0.020 |
Why?
|
| Th2 Cells | 1 | 2009 | 257 | 0.020 |
Why?
|
| Th1 Cells | 1 | 2009 | 250 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2009 | 317 | 0.020 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2009 | 171 | 0.020 |
Why?
|
| Infant | 1 | 2023 | 13310 | 0.020 |
Why?
|
| Models, Biological | 1 | 2016 | 3254 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2023 | 7551 | 0.020 |
Why?
|
| Arthritis, Experimental | 1 | 2007 | 47 | 0.020 |
Why?
|
| Haplotypes | 1 | 2009 | 856 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2023 | 16273 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2023 | 7702 | 0.020 |
Why?
|
| Vinculin | 1 | 2006 | 18 | 0.020 |
Why?
|
| Reticulin | 1 | 2006 | 22 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2007 | 241 | 0.020 |
Why?
|
| Tissue Culture Techniques | 1 | 2006 | 114 | 0.020 |
Why?
|
| Gene Expression | 1 | 2014 | 3570 | 0.020 |
Why?
|
| Comorbidity | 1 | 2012 | 2352 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2010 | 2316 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 3343 | 0.020 |
Why?
|
| Registries | 1 | 2012 | 2170 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2013 | 6150 | 0.010 |
Why?
|
| Actins | 1 | 2006 | 608 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2009 | 1549 | 0.010 |
Why?
|
| Affect | 1 | 2003 | 288 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2010 | 2086 | 0.010 |
Why?
|
| Transfection | 1 | 2006 | 2944 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2011 | 9180 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2003 | 2307 | 0.010 |
Why?
|
| Survival Rate | 1 | 2012 | 12221 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2003 | 904 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 29902 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2003 | 1467 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 14889 | 0.010 |
Why?
|
| Texas | 1 | 2003 | 6311 | 0.010 |
Why?
|
| Neoplasms | 1 | 2003 | 15193 | 0.000 |
Why?
|